Antineoplastic Effects of siRNA against TMPRSS2-ERG Junction Oncogene in Prostate Cancer

Area of Science:

• Oncology
• Molecular Biology
• Gene Therapy

Background:

• The TMPRSS2-ERG fusion oncogene is a prevalent driver in over 50% of prostate cancer cases.
• Its expression is often linked to poor patient prognosis, highlighting its significance in cancer progression.

Purpose of the Study:

• To achieve gene knockdown of the TMPRSS2-ERG fusion oncogene using small interfering RNA (siRNA).
• To evaluate the biological consequences of inhibiting this oncogene.
• To develop a potential therapeutic strategy for prostate cancer.

Main Methods:

• Designed and tested siRNAs targeting common TMPRSS2-ERG fusion variants (III and IV).
• Assessed mRNA and protein expression levels post-siRNA treatment.
• Utilized microarray analysis to identify downstream gene expression changes.
• Conjugated effective siRNA to squalene to form nanoparticles for in vivo delivery.
• Evaluated therapeutic efficacy in a VCaP xenograft mouse model.

Main Results:

• Two siRNAs demonstrated efficient inhibition of TMPRSS2-ERG mRNA and ERG protein.
• Microarray analysis revealed ADRA2A as a common downregulated gene involved in proliferation and migration.
• siRNA targeting variant IV exhibited significant anti-proliferative effects, increased apoptosis, and inhibited anti-apoptotic proteins.
• Squalene-conjugated siRNA nanoparticles reduced tumor growth, inhibited oncoprotein expression, and partially restored differentiation in vivo.

Conclusions:

• siRNA-mediated knockdown of TMPRSS2-ERG is a viable strategy for prostate cancer treatment.
• Squalene nanoparticles offer a promising delivery system for siRNA therapeutics targeting this oncogene.
• This approach presents a novel therapeutic prospect for prostate cancer patients harboring the TMPRSS2-ERG fusion.